Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent
EuroIntervention 2013;9:308-315 published online ahead of print May 2013. DOI: 10.4244/EIJV9I3A52
Ian T. Meredith1*, MBBS, PhD; Stefan Verheye2, MD, PhD; Neil J. Weissman3, MD; Paul Barragan4, MD; Douglas Scott5, MBChB; Mariano Valdés Chávarri6, MD, PhD; Nick E. J. West7, MD; Henning Kelbæk8, MD, DMSci; Robert Whitbourn9, MD; Darren L. Walters10, MBBS, MPhil; Jacek Kubica11, MD, PhD; Leif Thuesen12, MD; Monica Masotti13, MD, PhD; Adrian Banning14, MD; Iwar Sjögren15, MD; Rod H. Stables16, MA, DM; Dominic J. Allocco17, MD; Keith D. Dawkins17, MD
1. MonashHeart, Clayton, Victoria, Australia; 2. Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, Belgium; 3. MedStar Health Research Institute, Washington, DC, USA; 4. Polyclinique Les Fleurs, Ollioules, France; 5. Middlemore Hospital
Aims: The EVOLVE FHU trial demonstrated non-inferiority of six-month late loss with two dose formulations of SYNERGY, a novel bioabsorbable poly
